Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084758 | 0.93 | NAAA (0.63) | NAAADNM1TSHRL3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10882499 | 0.91 | NAAA (0.61) | NAAADNM1TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL19592492 | 0.88 | DNM1 (0.47) | NAAADNM1TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL5382868 | 0.86 | DNM1 (0.62) | NAAADNM1ALDH1A1GAACHRM2 | |
| SCHEMBL19945709 | 0.85 | DNM1 (0.62) | NAAADNM1TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL29120984 | 0.84 | DNM1 (0.61) | NAAADNM1TSHRL3MBTL1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28820114 | 0.84 | DNM1 (0.60) | NAAADNM1ALDH1A1GAACHRM2 | |
| SCHEMBL20115251 | 0.84 | DNM1 (0.56) | NAAADNM1TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL2600809 | 0.83 | NAAA (0.73) | NAAADNM1TSHRALDH1A1GAA | |
| SCHEMBL50185 | 0.83 | NAAA (0.81) | NAAADNM1TSHRALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| EP-4218722-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3860561-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-10981900-B2 | Spiro compound and use thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-10959926-B2 | Hair treatment agent with a polyvalent metal cation I | HENKEL AG & CO. KGAA (DE) | 2021-03-30 | — | — | US | disclosed |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-10-06 | — | — | US | disclosed |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-08-04 | — | — | US | disclosed |
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-02-13 | — | — | US | disclosed |
| EP-3191487-B1 | SPIROCYCLIC INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3511331-A1 | SPIROCYCLIC INHIBITORS OF CATHEPSIN C | Boehringer Ingelheim International GmbH (DE) | 2019-07-17 | — | — | EP | disclosed |
| WO-2013086322-A1 | BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086354-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-8354445-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-01-15 | — | — | US | disclosed |
| WO-2011153493-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| US-8030344-B2 | Such as (S)-2-(Dimethylamino)ethyl-1-(4-(2-aminophenylcarbamoyl)-phenyl)pyrrolidin-3-ylcarbamate for treating cell proliferative disorders | METHYLGENE INC. (CA) | 2011-10-04 | — | — | US | disclosed |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-5851681-A | Wiring structure with metal wiring layers and polyimide layers, and fabrication process of multilayer wiring board | HITACHI, LTD. (JP) | 1998-12-22 | — | — | US | disclosed |
| US-4352913-A | EPOXY RESIN CURING AGENTS | CIBA-GEIGY CORPORATION (US) | 1982-10-05 | — | — | US | disclosed |
| US-4324739-A | CURING AGENTS FOR POLYEPOXIDES | CIBA-GEIGY CORPORATION (US) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | NAAA 755/4885DNM1 3189/4885TSHR 3279/4885 |
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | S1PR1, S1PR2, S1PR3 | NAAA 3933/4885DNM1 2571/4885TSHR 682/4885 |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | NAAA 755/4885DNM1 3189/4885TSHR 3279/4885 |
| US-10981900-B2 | Spiro compound and use thereof | S1PR1, S1PR2, S1PR3 | NAAA 3933/4885DNM1 2571/4885TSHR 682/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | NAAA 693/4885DNM1 472/4885TSHR 2733/4885 |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | NAAA 1920/4885DNM1 1249/4885TSHR 1112/4885 |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | NAAA 1920/4885DNM1 1249/4885TSHR 1112/4885 |
| US-10959926-B2 | Hair treatment agent with a polyvalent metal cation I | FH, FTH1, ACIN1 | NAAA 91/4885DNM1 1419/4885TSHR 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.